Vincent Peterkin

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Barry C. Jones, Jeffrey R. Koup, Dennis A. Smith, 2004, Drug Metabolism and Disposition.

Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes.

Michael Z. Man, J. Paulauskis, J. Bauman, 2007, British journal of clinical pharmacology.

Drug-drug interactions for UGT substrates: a pharmacokinetic explanation for typically observed low exposure (AUC i /AUC) ratios

Dennis A. Smith, J. Williams, J. Koup, 2004 .

Modulation of cellular S1P levels with a novel, potent and specific inhibitor of sphingosine kinase-1.

T. Kasten, J. Chrencik, A. Wittwer, 2012, The Biochemical journal.

Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.

J. Randolph, Hui-ju Chen, Deanne F. Stolarik, 2020, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus.

J. Randolph, R. Henry, Hui-ju Chen, 2019, Bioorganic & medicinal chemistry.

A Humanized UGT1 Mouse Model Expressing the UGT1A1*28 Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation

R. Tukey, J. Stevens, Shujuan Chen, 2010, Drug Metabolism and Disposition.